FDA Issues Guidance on Pediatric Studies of Molecularly Targeted Oncology Drugs
The guidance addresses implementation of amendments made by the FDA Reauthorization Act of 2017.
FDA published final guidance on May 24, 2021 for the early planning of pediatric evaluation of molecularly targeted oncology drugs as required by section 505B(a)(1)(B) of the Federal Food, Drug, & Cosmetic Act (FD&C), as amended by the FDA Reauthorization Act of 2017 (FDARA). The guidance document addresses molecularly targeted oncology drugs where original New Drug Applications (NDAs) and Biologics License Applications (BLAs) are submitted to FDA. FDA expects early pediatric evaluation of these drugs to accelerate the creation of a pediatric development plan and development of pediatric oncology drugs.
Specifically, the document discusses regulatory considerations such as molecular target, determination of relevance, target lists, recommended studies, and rare cancers. It also addresses international collaboration in development of these drugs.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
